Delayed thrombin generation is not associated with fibrinopeptide formation during prolonged cardiopulmonary bypass with hirudin anticoagulation

Belway, D.; Rubens, F. D.; Henley, B.; Babaev, A.; Mesana, T.
September 2006
Perfusion;Sep2006, Vol. 21 Issue 5, p259
Academic Journal
Patients with heparin-induced thrombocytopenia urgently requiring surgery with cardiopulmonary bypass (CPB) present a unique management challenge that must be addressed by the use of alternative anticoagulants. Although clinical success with the direct thrombin inhibitor hirudin has been reported, there is sparse information in the literature supporting the efficacy of this drug as an anti-thrombotic to prevent fibrin formation during CPB. In this report, we describe the efficacy of this drug to prevent thrombin-mediated fibrin formation during CPB.


Related Articles

  • A Comparison of Heparin and New Anticoagulants for Cardiopulmonary Bypass Surgery. Belougne-Malfattie, Emmanuelle; Aguejouf, Omar; Labrousse, Louis; Doutremepuich, Christian // Clinical & Applied Thrombosis/Hemostasis;Apr1998, Vol. 4 Issue 2, p118 

    Heparin is still the major anticoagulant of choice during CPB. but it may cause thrombocytopenia and severe bleeding in patients. In light of these complications, the development of new anticoagulant drugs seemed to be necessary for these patients. Many experimental studies focused on r-hirudin,...

  • Novel techniques in the use of bivalirudin for cardiopulmonary bypass anticoagulation in a child with heparin-induced thrombocytopenia. Dragomer, D; Chalfant, A; Biniwale, R; Reemtsen, B; Federman, M // Perfusion;Nov2011, Vol. 26 Issue 6, p516 

    Heparin-induced thrombocytopenia (HIT) occurs in both the pediatric and adult populations after exposure to heparin. Bivalirudin has been used as an alternative to heparin for adults undergoing cardiac surgery and cardiopulmonary bypass, but has only been used minimally in children for this...

  • Gabexate mesilate and antithrombin III for intraoperative anticoagulation in heparin pretreated patients. Ranucci, M.; Cazzaniga, A.; Isgrò, G.; Ditta, A.; Boncilli, A.; Cotza, M.; Brozzi, S. // Perfusion;1999, Vol. 14 Issue 5, p357 

    Thirty patients scheduled for elective myocardial revascularization and having undergone preoperative heparin treatment have been admitted to this prospective, randomized study. The aim of the study was to test two different strategies for preserving circulating antithrombin III (AT-III) during...

  • Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin allergy. Pappalardo, F.; Franco, A.; G., G. Crescenzi; Poli, A.; Zangrillo, A.; Koster, A. // Perfusion;Jan2007, Vol. 22 Issue 1, p67 

    Heparin-induced IgE-mediated hypersensitivity and anaphylactoid reactions, although rare, can pose a serious clinical problem for patients requiring cardiopulmonary bypass (CPB). Bivalirudin is a bivalent reversible direct thrombin inhibitor, with a half-life of 25 min, eliminated mostly by...

  • Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass. Agarwal, Shvetank; Ullom, Beth; Al-Baghdadi, Yasser; Okumura, Michael // Journal of Anaesthesiology Clinical Pharmacology;Jan2012, Vol. 28 Issue 1, p106 

    Use of argatroban as an alternative to heparin during cardiopulmonary bypass (CPB) in patients with heparin-induced thrombocytopenia has gained some attention in the past two decades. Dosing of argatroban during CPB is complex due to lack of complete understanding of its pharmacokinetic profile...

  • Thrombocytopenia Associated with Antithrombotic Therapy in Patients with Cardiovascular Diseases: Diagnosis and Treatment. Kilickiran Avci, Burcak; Oto, Ali; Ozcebe, Osman // American Journal of Cardiovascular Drugs;2008, Vol. 8 Issue 5, p327 

    Agents with antiplatelet and anticoagulant activity have been proved to be effective in reducing the incidence of complications following acute coronary syndrome, percutaneous coronary intervention, and cardiopulmonary bypass. However, these agents, including heparin, glycoprotein IIb/IIIa...

  • Management of coagulation during cardiopulmonary bypass. O'Carroll-Kuehn, Britta U.; Meeran, Hanif // Continuing Education in Anaesthesia, Critical Care & Pain;Dec2007, Vol. 7 Issue 6, p195 

    The article presents information on the management of coagulation during cardiopulmonary bypass. It states that coagulation and inflammatory pathways occur by contact of the blood with the cardiopulmonary bypass (CPB) circuit and surgical wound during open heart surgery. The mechanism of action...

  • Non-recovery of ACT in a patient with heparin-induced thrombocytopenia type II during mitral valve replacement using argatroban anticoagulation. Tanigawa, Yoshinori; Yamada, Tomoko; Matsumoto, Koichi; Nakagawachi, Akira; Torikai, Arisu; Sakaguchi, Yoshirou // Journal of Anesthesia;Dec2013, Vol. 27 Issue 6, p951 

    Argatroban was used as the anticoagulant during cardiopulmonary bypass (CPB) in a patient with heparin-induced thrombocytopenia (HIT) type II undergoing mitral valve replacement. Dosage was reduced because of preoperative congestive liver disorder. Perioperative coagulability was poor, and,...

  • Alternatives to unfractioned heparin for anticoagulation in cardiopulmonary bypass. von Segesser, L.K.; Mueller, X.; Marty, B.; Horisberger, J.; Corno, A. // Perfusion;Sep2001, Vol. 16 Issue 5, p411 

    Despite the progress made in the development of cardiopulmonary bypass (CPB) equipment, systemic anticoagulation with unfractioned heparin and post-bypass neutralization with protamine are still used in most perfusion procedures. However, there are a number of situations where unfractioned...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics